RecruitingNCT04792684
Collection of Samples USOPTIVAL Study
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance ("USOPTIVAL")
Sponsor
Universal Diagnostics
Enrollment
1,300 participants
Start Date
Dec 30, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Eligibility
Min Age: 45 YearsMax Age: 84 Years
Inclusion Criteria8
- Arm A:
- Must be 45-84 years of age.
- Must have a suspected advanced adenoma or be newly diagnosed with CRC, still not resected, and scheduled for surgery.
- Able to comprehend, sign, and date the written informed consent document.
- Arm B:
- Must be 45-84 years of age.
- Able and willing to undergo a standard-of-care screening colonoscopy within 60 days.
- Able to comprehend, sign, and date the written informed consent document.
Exclusion Criteria20
- Arm A Only:
- \. Subject with curative biopsy during colonoscopy.
- Arm B Only:
- Subjects with positive FIT Test results in the 6 months preceding enrollment.
- Subject has a current diagnosis of cancer.
- Arms A \& B:
- Subject has a personal history of aerodigestive or digestive tract cancers.
- Subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer.
- Has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer:
- Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
- Familial adenomatous polyposis ("FAP", including attenuated FAP).
- Hereditary non-polyposis colorectal cancer syndrome ("HNPCC" or "Lynch Syndrome").
- Serrated polyposis syndrome
- first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer.
- One first-degree relative with CRC diagnosed before the age of 60.
- A significant disease which, in the Investigator's opinion, would exclude the subject from the study.
- Legal incapacity or limited mental capacity.
- Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent.
- The patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (E.g. Hepatitis, HIV, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions.
- The patient is known to be pregnant when recruited or during her participation in the study.
Interventions
DIAGNOSTIC_TESTOptimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Evaluate the performance of a preliminary panel of biomarkers
Locations(16)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04792684
Related Trials
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT072230478 locations
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
NCT074635991 location
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT068950311 location
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
NCT074481421 location
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT073495375 locations